InterCure Ltd. Announces 1-for-5 Reverse Share Split

Rhea-AI Summary

InterCure (Nasdaq: INCR) plans a 1-for-5 reverse share split of its ordinary shares, effective at market open on August 24, 2026, when trading will begin on a split-adjusted basis under the same ticker. The new CUSIP will be M549GJ368.

The move aims to raise InterCure’s share price to regain compliance with Nasdaq’s $1.00 minimum bid requirement and support continued listing. Shareholders approved the action on August 11, 2026. Authorized share capital will adjust from 100,000,000 to 20,000,000 ordinary shares, and issued and outstanding shares from 59,228,556 to about 11,845,711, with fractional shares rounded down.

Positive

• 1-for-5 reverse split designed to support Nasdaq bid-price compliance
• Authorized share capital reduced from 100,000,000 to 20,000,000 ordinary shares
• Outstanding shares adjusted from 59,228,556 to approximately 11,845,711 post-split
• Shareholder approval obtained at August 11, 2026 extraordinary general meeting

Negative

• Nasdaq bid-price noncompliance with August 24, 2026 deadline
• Expected Staff Delisting Determination from Nasdaq, requiring a formal appeal
• Fractional shares rounded down, slightly reducing holdings for some shareholders

News Explained

The split changes share units, but Nasdaq compliance remains unresolved and an appeal is expected before listing status is settled.

The scheduled split is not the end of the listing process: InterCure says the compliance period will extend beyond August 24, 2026, so it expects a Nasdaq Staff Delisting Determination and intends to appeal.

The company expects its shares to continue trading on Nasdaq during the appeal while it seeks to demonstrate compliance.

Beyond ordinary shares, the split will proportionally adjust shares underlying outstanding options and warrants, restricted shares, restricted share units, and share-plan and certain agreement share amounts; warrant exercise prices will also be adjusted under their terms.

In general, a reverse split consolidates shares and raises the per-share price proportionally without changing company value by the split itself; InterCure says the split will not change holders’ percentage ownership except for minor fractional-share effects.

Market Context

INCR recorded a 2.4% 24-hour reaction to its prior Nasdaq minimum-bid notice, despite the compliance...

Analysis

INCR recorded a 2.4% 24-hour reaction to its prior Nasdaq minimum-bid notice, despite the compliance concern. That history adds context to this split, while low short positioning remained a relevant risk factor to monitor.

Key Figures

Reverse Split Ratio: 1-for-5 Trading Date: August 24, 2026 Minimum Bid Requirement: $1.00 +3 more

6 metrics

Reverse Split Ratio 1-for-5 Reverse Share Split

Trading Date August 24, 2026 Split-adjusted trading begins

Minimum Bid Requirement $1.00 Nasdaq continued listing compliance

Authorized Shares 100,000,000 to 20,000,000 Adjustment to authorized share capital

Issued and Outstanding Shares 59,228,556 to approximately 11,845,711 Following the Reverse Share Split

Shareholder Approval Date August 11, 2026 Extraordinary General Meeting

Historical Context

4 past events · Latest: Jun 22 (Negative)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	private placement	Negative	+17.4%	Private placement financing included potential warrant-related dilution and facility recovery funding.
Jun 15	acquisition	Positive	+9.3%	Botanico acquisition expanded U.S. cannabis genetics, brands, technology, and operator alliances.
Apr 30	2025 results	Positive	+5.5%	Results included NIS 270.2 million revenue and positive operating cash flow.
Mar 03	Nasdaq compliance notice	Negative	+2.4%	Nasdaq notification cited failure to meet the $1.00 minimum bid requirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

INCR recorded positive 24-hour reactions across all four recent general-news events, including financing and Nasdaq compliance news.

Key Terms

reverse share split, cusip number, minimum bid price requirement, split-adjusted basis, +1 more

5 terms

reverse share split financial

"today announced that it intends to effect a one-for-five reverse split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

cusip number technical

"The new CUSIP number for the Ordinary Shares following the Reverse Share Split"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

minimum bid price requirement regulatory

"regain compliance with the $1.00 minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

split-adjusted basis financial

"will begin trading on a split-adjusted basis when the market opens"

An adjustment to historical share prices and share counts that reflects past stock splits or reverse splits so that old data lines up with the current number of shares. Think of it like resizing an old photograph so it matches a new frame: it keeps price charts, returns and per‑share metrics comparable over time, which matters to investors who need accurate performance, valuation and trend analysis.

good manufacturing practices regulatory

"offer Good Manufacturing Practices (GMP) certified"

Good manufacturing practices are a set of required processes, controls and documentation that ensure products are made consistently, safely and to quality standards — like following a precise recipe in a clean kitchen so every batch turns out the same. For investors, compliance matters because it affects a maker’s ability to get regulatory approval, avoid costly recalls or production stoppages, and maintain customer and market trust, all of which influence revenue and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Strategic Action Aimed at Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Protecting Continued Listing Status

NEW YORK and HERTZLIYA, ISRAEL, Aug. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (the “Company” or “InterCure”) (Nasdaq: INCR), today announced that it intends to effect a one-for-five reverse split (the "Reverse Share Split") of the Company’s ordinary shares, no par value per share, (the "Ordinary Shares"). The Ordinary Shares will continue to trade on the Nasdaq Global Market under the existing symbol “INCR”, and will begin trading on a split-adjusted basis when the market opens on August 24, 2026. The new CUSIP number for the Ordinary Shares following the Reverse Share Split will be M549GJ368.

The primary purpose of the Reverse Share Split is to increase the per-share trading price of the Company’s Ordinary Shares to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market. Because the requisite compliance period will extend beyond the Company’s current August 24, 2026 deadline, the Company expects to receive a Staff Delisting Determination from Nasdaq and intends to timely appeal any such determination. The Company expects its Ordinary Shares to continue trading on Nasdaq during the appeal process while it seeks to demonstrate compliance.

The Reverse Share Split was approved by the Company's shareholders at the Company’s Extraordinary General Meeting of Shareholders held on August 11, 2026. The Reverse Share Split will result in an adjustment to the authorized share capital of the Company under the Company’s articles of association, as currently in effect (the “Articles”), from 100,000,000 Ordinary Shares to 20,000,000 Ordinary Shares.

The Reverse Share Split will affect all shareholders uniformly and will not alter any shareholder’s percentage ownership interest in the Company’s equity, except for minor changes to the treatment of fractional shares as described below. The Reverse Share Split will adjust the number of issued and outstanding Ordinary Shares of the Company from 59,228,556 Ordinary Shares to approximately 11,845,711 Ordinary Shares (subject to any further adjustments based on the treatment of fractional shares). In accordance with the Company’s Articles, no fractional Ordinary Shares will be issued as a result of the Reverse Share Split. The Company’s board of directors approved that all fractional Ordinary Shares shall be rounded down to the nearest whole Ordinary Share. Proportional adjustments also will be made to Ordinary Shares underlying outstanding options and warrants (and the exercise price shall be adjusted pursuant to the terms of the respective warrants), restricted shares, restricted share units, and to the number of Ordinary Shares issued and issuable under the Company’s share incentive plans and certain existing agreements.

Equiniti Trust Company, LLC, the Company’s transfer agent, will send instructions to shareholders of record who hold share certificates regarding the exchange of certificates for Ordinary Shares. Shareholders who hold their Ordinary Shares in book-entry form or in brokerage accounts or “street name” are not required to take any action to effect the exchange of their Ordinary Shares following the Reverse Share Split.

About InterCure Ltd.

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the implementation of the Reverse Share Split, the effective date for the Reverse Share Split, the date on which trading of the Ordinary Shares will begin on a split-adjusted, any treatment of fractional shares, the expectation of the Company to increase the per-share trading price of its Ordinary Shares, the Company’s ability to regain and maintain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co

FAQ

What is InterCure (INCR) announcing in its August 19, 2026 reverse share split?

InterCure is implementing a 1-for-5 reverse share split of its ordinary shares. According to InterCure, the action consolidates every five existing shares into one new share to help raise the trading price and support Nasdaq listing requirements.

When will the InterCure (INCR) 1-for-5 reverse share split take effect?

The InterCure reverse share split becomes effective at market open on August 24, 2026. According to InterCure, shares will begin trading on a split-adjusted basis that day on the Nasdaq Global Market under the existing ticker symbol INCR.

How will the InterCure (INCR) reverse split affect outstanding and authorized shares?

The reverse split will cut authorized shares from 100,000,000 to 20,000,000 and outstanding shares from 59,228,556 to about 11,845,711. According to InterCure, proportional adjustments will also apply to options, warrants and equity plans.

Why is InterCure (INCR) doing a reverse share split and how is it tied to Nasdaq compliance?

InterCure aims to increase its share price to meet Nasdaq’s $1.00 minimum bid requirement. According to InterCure, the reverse split is a strategic action to help regain compliance and protect its continued listing on the Nasdaq Global Market.

What happens to fractional shares in the InterCure (INCR) 1-for-5 reverse split?

No fractional shares will be issued in the reverse split; amounts are rounded down to the nearest whole share. According to InterCure, this may cause minor changes in individual holdings but does not alter overall percentage ownership materially.

Will InterCure (INCR) be delisted from Nasdaq because of the reverse split and compliance deadline?

InterCure expects a Nasdaq Staff Delisting Determination because the compliance period extends beyond August 24, 2026. According to InterCure, it intends to appeal and expects its ordinary shares to continue trading on Nasdaq during the appeal process.

Do InterCure (INCR) shareholders need to take action for the reverse share split?

Shareholders with book-entry or street-name holdings generally do not need to act. According to InterCure, the transfer agent will send instructions only to registered holders with share certificates on how to exchange certificates for split-adjusted ordinary shares.